Olaparib in Patients With Solid Tumors With <i>ATM</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Olaparib met the prespecified criteria to declare a signal of activity in patients with <i>ATM</i>-altered cancer within the LC and HP cohorts but not the CRC or PC cohorts.